These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. A novel TCR-like CAR with specificity for PR1/HLA-A2 effectively targets myeloid leukemia in vitro when expressed in human adult peripheral blood and cord blood T cells. Ma Q; Garber HR; Lu S; He H; Tallis E; Ding X; Sergeeva A; Wood MS; Dotti G; Salvado B; Ruisaard K; Clise-Dwyer K; John LS; Rezvani K; Alatrash G; Shpall EJ; Molldrem JJ Cytotherapy; 2016 Aug; 18(8):985-994. PubMed ID: 27265873 [TBL] [Abstract][Full Text] [Related]
10. Targeting CAR to the Peptide-MHC Complex Reveals Distinct Signaling Compared to That of TCR in a Jurkat T Cell Model. Wu L; Brzostek J; Sankaran S; Wei Q; Yap J; Tan TYY; Lai J; MacAry PA; Gascoigne NRJ Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33670734 [TBL] [Abstract][Full Text] [Related]
11. A Novel Peptide-MHC Targeted Chimeric Antigen Receptor T Cell Forms a T Cell-like Immune Synapse. Wang SS; Luong K; Gracey FM; Jabar S; McColl B; Cross RS; Jenkins MR Biomedicines; 2021 Dec; 9(12):. PubMed ID: 34944696 [TBL] [Abstract][Full Text] [Related]
12. Anti-melanoma activity of T cells redirected with a TCR-like chimeric antigen receptor. Zhang G; Wang L; Cui H; Wang X; Zhang G; Ma J; Han H; He W; Wang W; Zhao Y; Liu C; Sun M; Gao B Sci Rep; 2014 Jan; 4():3571. PubMed ID: 24389689 [TBL] [Abstract][Full Text] [Related]
13. Rational development of high-affinity T-cell receptor-like antibodies. Stewart-Jones G; Wadle A; Hombach A; Shenderov E; Held G; Fischer E; Kleber S; Nuber N; Stenner-Liewen F; Bauer S; McMichael A; Knuth A; Abken H; Hombach AA; Cerundolo V; Jones EY; Renner C Proc Natl Acad Sci U S A; 2009 Apr; 106(14):5784-8. PubMed ID: 19307587 [TBL] [Abstract][Full Text] [Related]
14. Emerging immunotherapeutics in adenocarcinomas: A focus on CAR-T cells. Yazdanifar M; Zhou R; Mukherjee P Curr Trends Immunol; 2016; 17():95-115. PubMed ID: 28659689 [TBL] [Abstract][Full Text] [Related]
16. Single-Domain Antibody-Based TCR-Like CAR-T: A Potential Cancer Therapy. Zhu L; Yang X; Zhong D; Xie S; Shi W; Li Y; Hou X; HuaYao ; Zhou H; Zhao M; Ding Z; Zhao X; Mo F; Yin S; Liu A; Lu X J Immunol Res; 2020; 2020():2454907. PubMed ID: 32964055 [TBL] [Abstract][Full Text] [Related]
17. Chimeric STAR receptors using TCR machinery mediate robust responses against solid tumors. Liu Y; Liu G; Wang J; Zheng ZY; Jia L; Rui W; Huang D; Zhou ZX; Zhou L; Wu X; Lin S; Zhao X; Lin X Sci Transl Med; 2021 Mar; 13(586):. PubMed ID: 33762437 [TBL] [Abstract][Full Text] [Related]
18. Development of a T-cell receptor mimic antibody targeting a novel Wilms tumor 1-derived peptide and analysis of its specificity. Kurosawa N; Midorikawa A; Ida K; Fudaba YW; Isobe M Cancer Sci; 2020 Oct; 111(10):3516-3526. PubMed ID: 32770595 [TBL] [Abstract][Full Text] [Related]
19. The analysis of the natural killer-like activity of human cytolytic T lymphocytes revealed HLA-E as a novel target for TCR alpha/beta-mediated recognition. Pietra G; Romagnani C; Falco M; Vitale M; Castriconi R; Pende D; Millo E; Anfossi S; Biassoni R; Moretta L; Mingari MC Eur J Immunol; 2001 Dec; 31(12):3687-93. PubMed ID: 11745389 [TBL] [Abstract][Full Text] [Related]
20. A CD22-reactive TCR from the T-cell allorepertoire for the treatment of acute lymphoblastic leukemia by TCR gene transfer. Jahn L; Hagedoorn RS; van der Steen DM; Hombrink P; Kester MG; Schoonakker MP; de Ridder D; van Veelen PA; Falkenburg JH; Heemskerk MH Oncotarget; 2016 Nov; 7(44):71536-71547. PubMed ID: 27689397 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]